Company intelligence / Profile preview

6539718 Canada

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

6539718 Canada Inc. was a Canadian biotechnology entity primarily known as a shell or holding company used during the acquisition of assets related to metabolic disease research. The company was notably involved in the transaction where Eli Lilly and Company acquired the rights to certain GLP-1 receptor agonist programs. Its primary focus was the development of oral small molecule therapies for type 2 diabetes and obesity. Following the integration of its intellectual property into the acquirer's portfolio, the entity ceased independent operations.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Eli Lilly

Beyond the preview

Go deeper on 6539718 Canada.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6539718 Canada.

Explore the full profile